指南与共识冠心病血脂与心血管预防

脂蛋白(a)与日本冠心病患者达标后残余心血管风险

Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended low-density lipoprotein cholesterol goals.
指南 / 共识 · Eur Heart J · 2026-01-01

本研究为多中心回顾性观察研究,纳入1581例日本冠心病患者,分析PCI术后8周LDL-C分层(<55 vs ≥55 mg/dL)与Lp(a)水平对MACE风险的影响。结果显示,即使LDL-C<55 mg/dL,Lp(a)≥30 mg/dL及≥50 mg/dL仍与MACE风险显著升高相关(adjusted HR分别为3.80和6.90)。ROC分析提示Lp(a)≥28.2 mg/dL为MACE阈值。

要点

  • LDL-C<55 mg/dL时,Lp(a)≥30 mg/dL仍增加MACE风险(adjusted HR=3.80)。
  • Lp(a)≥50 mg/dL者5年MACE率33.4%,adjusted HR=6.90。
  • 日本CAD患者Lp(a)风险阈值可能低于白种人群(≥28.2 mg/dL)。

核心结论

  • 降低LDL-C可部分减轻Lp(a)相关风险,但高Lp(a)仍与更差心血管结局相关。
  • 日本CAD患者复发事件风险的Lp(a)阈值似乎低于白种人群,需进一步评估。

研究设计与样本

  • 多中心回顾性观察研究,纳入1581例日本冠心病患者(Lp(a)-JAPAN: jRCT1050260016)。
  • PCI术后8周按LDL-C(<55 vs ≥55 mg/dL)和Lp(a)(<30、≥30且<50、≥50 mg/dL)分层比较MACE风险。
  • MACE定义:心源性死亡+非致死性心肌梗死+非罪犯段冠状动脉血运重建。

主要发现

  • LDL-C≥55 mg/dL组(n=1069)MACE发生率21.3%,Lp(a)<30、≥30且<50、≥50 mg/dL的事件率分别为3.9、7.9、11.0例/100人年(log-rank p<0.001)。
  • LDL-C<55 mg/dL组(n=512)MACE总体比例4.3%(p<0.001),但Lp(a)升高仍识别高风险者,事件率分别为1.4、4.7、7.5例/100人年(p<0.001)。
  • 标准化5年MACE率:Lp(a)<30 mg/dL为5.0%,Lp(a)≥30且<50 mg/dL为17.0%(adjusted HR=3.80,95%CI 1.78-8.11,p<0.001),Lp(a)≥50 mg/dL为33.4%(adjusted HR=6.90,95%CI 3.53-13.46,p<0.001)。
  • ROC分析确定Lp(a)≥28.2 mg/dL为MACE阈值(AUC=0.68,p<0.001)。

关键数值与推荐

  • LDL-C目标:<55 mg/dL vs ≥55 mg/dL(PCI术后8周)。
  • Lp(a)分层:<30、≥30且<50、≥50 mg/dL。
  • Lp(a)≥28.2 mg/dL为MACE的ROC阈值(AUC=0.68,p<0.001)。

临床怎么用

  • 对已达标LDL-C<55 mg/dL的CAD患者,仍应检测Lp(a)以识别残余风险。
  • Lp(a)≥30 mg/dL尤其≥50 mg/dL提示MACE风险显著升高,需加强监测与危险因素管理。
  • 日本CAD患者Lp(a)风险阈值可能更低(≥28.2 mg/dL),临床解读需考虑人群差异。

局限性

  • 回顾性观察设计,可能存在残余混杂。
  • 研究人群为日本CAD患者,结论外推需谨慎。
  • Lp(a)降低治疗不可用,未评估干预效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Current guidance recommends better LDL-C control in patients with elevated Lp(a) as Lp(a) lowering therapies are unavailable. Whether risks attributable to Lp(a) are mitigated in patients with CAD who achieved LDL-C <55 mg/dL remains unknown. METHODS: Multicentre retrospective observational study analysed 1581 Japanese patients with CAD [Lp(a)-JAPAN: jRCT1050260016]. Risk of MACE (cardiac-caused death + nonfatal MI + coronary revascularization in non-culprit segments) was compared according to Lp(a) levels (<30, ≥30, and <50 mg/dL and ≥50 mg/dL) and amongst LDL-C strata (<55 mg/dL vs ≥55 mg/dL) 8 weeks after PCI. RESULTS: During the 5.1-year observation amongst patients with LDL-C ≥55mg/dL (n=1069), MACE occurred in 21.3% with risk of MACE increasing with Lp(a) levels (3.9, 7.9, and 11.0 events per 100 person-years for <30, ≥30, and <50 mg/dL and ≥50 mg/dL, log-rank p<0.001). Amongst those with LDL-C <55mg/dL (n=512), the proportion with MACE was lower overall (4.3%, p<0.001). However, elevated Lp(a) levels still identified those at higher risk of MACE (1.4, 4.7, and 7.5 events per 100 person-years in Lp(a) <30, ≥30, and <50 mg/dL and ≥50 mg/dL, p<0.001). Standardized 5-year MACE rate was over twice and five times higher in patients with Lp(a) ≥30 and <50 mg/dL (17.0%: adjusted HR = 3.80, 95% CI = 1.78-8.11, p<0.001) and ≥50 mg/dL (33.4%: adjusted HR = 6.90, 95% CI = 3.53-13.46, p<0.001) compared to Lp(a) <30 mg/dL (5.0%), respectively. The ROC analyses identified Lp(a) ≥28.2 mg/dL as the threshold for MACE (AUC = 0.68, p<0.001). CONCLUSIONS: Whilst lower achieved LDL-C attenuates in part the risk from Lp(a), elevated Lp(a) levels still associate with worse cardiovascular outcomes. The Lp(a) threshold amongst Japanese patients with CAD at risk of recurrent events appears lower than in Caucasian populations which merits further evaluation.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kataoka Y, Ray KK, Nicholls SJ, et al. Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended low-density lipoprotein cholesterol goals. Eur Heart J. 2026. PMID: 42177636. doi:10.1093/eurheartj/ehag446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。